Shire plc
Shire: Q1 2006 statement
Shire’s revenue growth of 23% was boosted by the acquisition of Transkaryoritic Technologies but even stripping that out the effect of that underlying revenue growth of 15% is still very strong for a business as substantial as Shire - it may be much smaller than the major pharmaceutical companies but it is a FTSE100 companies.
Low […]
Shire Pharmaceuticals
Shire Pharmaceuticals’ revenues so far in the 2004/5 financial year has been strong with third quarter sales up 22% and operating profit up 16%.
Adderall XR (an amphetamine used for attention deficit hyperactivity disorder) continues to perform well with sales up $19m (+16%), but its sales in Canada have since been suspended. Although Canada is not […]
Random picks: Acambis | Avis | GKN | GCap Media | Scottish Power | Scottish & Southern Energy | Vodafone | Wellington Underwriting | Gallaher | Spirent